
AC Immune (ACIU) Stock Forecast & Price Target
AC Immune (ACIU) Analyst Ratings
Bulls say
AC Immune SA is strategically focused on developing innovative therapies for neurodegenerative diseases, particularly through its robust pipeline that includes notable candidates like ACI-7104.056, which has already shown a significant increase in antibodies against pathogenic variants of aSyn, reflecting the potential for efficacy in future readouts. Additionally, the company's NLRP3 program, leveraging a highly BBB-penetrant molecule, could see heightened interest following the outcomes of the upcoming EVOKE trial, positioning AC Immune favorably within a growing market for Alzheimer's disease treatment solutions.
Bears say
AC Immune SA reported a net operating loss of CHF 16.2 million for the quarter, highlighting ongoing financial challenges as it invests heavily in clinical development. The company navigates significant risks common in the biopharmaceutical industry, such as unexpected clinical readouts and regulatory uncertainties, which could adversely impact its prospects. Furthermore, the complexity and price sensitivity of commercial markets for its product candidates could hinder potential revenue generation and overall financial stability.
This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.
AC Immune (ACIU) Analyst Forecast & Price Prediction
Start investing in AC Immune (ACIU)
Order type
Buy in
Order amount
Est. shares
0 shares